Answers are grounded in this paper and cite their sources.
Shilpa Kuttikrishnanab, Kirti S. Prabhua, Abdul Q. Khana, Feras Q. Alalibc, Aamir Ahmadad & Shahab Uddinade* a Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatarb College of Pharmacy, Qatar University, Doha, Qatarc Biomedical and Pharmaceutical Research Unit, QU Health, Qatar Universityd Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatare Laboratory of Animal Research Center, Qatar University, Doha, QatarSupplemental data for this article can be accessed here.CONTACT Shahab Uddin SKhan34@hamad.qa Translational Research Institute, Academic Health System, Hamad Medical Corporation, PO Box 3050, Doha, QatarAbstractForkhead box M1 (FoxM1) is a transcription factor that plays an important role in the etiology of many cancers, however, its role has not been elucidated in B-precursor acute lymphoblastic leukemia (B-pre-ALL). In the current study, we showed that the downregulation of FoxM1 by its inhibitor thiostrepton inhibited cell viability and induced caspase-dependent apoptosis in a panel of B-pre-ALL cell lines. Thiostrepton led downregulation of FoxM1 accompanied by decreased expression of Aurora kinase A, B, matrix metalloproteinases, and oncogene SKP2 as well as MTH1. Downregulation of the FoxM1/SKP2/MTH1 axis led to increase in the Bax/Bcl2 ratio and suppression of antiapoptotic proteins. Thiostrepton-mediated apoptosis was prevented by N-acetyl cysteine, a scavenger of reactive oxygen species. Co-treatment of B-pre-ALL with subtoxic doses of thiostrepton and bortezomib potentiated the proapoptotic action. Altogether, our results suggest that targeting FoxM1expression could be an attractive strategy for the treatment of B-pre-ALL.
No takes yet. Share an insight, caveat, or question.
Kuttikrishnan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: